fbpx

NIP Vaccination in Pharmacy expansion improves equitable access to vaccines

20 April 2024

 

The Pharmaceutical Society of Australia (PSA) welcomes the Albanese Government’s expanded funding for National Immunisation Program Vaccination in Pharmacy (NIPVIP) program in aged care and disability homes from 29 April 2024, actioning one of PSA’s key recommendations in its 2024-25 Federal Budget Submission.

 

Ahead of World Immunisation Week beginning 24 April 2024, the Minister for Health and Aged Care, Hon Mark Butler MP, has announced that pharmacists will be funded to deliver National Immunisation Program vaccines to some of Australia’s most vulnerable priority population groups.

 

The Minister has also announced that NIPVIP payments will also be indexed in line with Medicare Benefits Schedule (MBS) indexation from 1 July 2024.

 

PSA Chief Executive Officer, Adjunct Associate Professor Steve Morris welcomed the move, which PSA – as the only peak body representing all of Australia’s 37,000 pharmacists – has been advocating for, to expand access to funded vaccination services to all pharmacists practising in all locations.

 

“The expansion of the National Immunisation Program Vaccination in Pharmacy program to include pharmacists practising in residential aged care facilities and in disability care will drastically improve the specialised care pharmacists provide to these patients,” Adj. A/Prof Morris said.

 

“PSA has been supportive of increased investment in pharmacist vaccination services, supporting the delivery of ‘all vaccines, to all ages, in all locations’ – and therefore, pharmacists welcome this announcement.

 

“It means pharmacists can deliver more services to the priority groups who are the most heavily reliant on vaccines.

 

“We are continuing to work with governments across Australia on improvements to the accessibility of vaccination services for all Australians ahead of the winter flu season.”

 

Adj. A/Prof Morris also welcomed the confirmation of service payment indexation in line with indexation of MBS service payments.

 

“Lifting remuneration to meet the rising costs of service delivery allows pharmacists to continue delivering critical vaccination clinics,” he said.

 

“Pharmacists continue to be some of the most accessible vaccination providers, supporting increased vaccination coverage around the country. Adequate pharmacist remuneration is critical to ensuring that these essential services delivered by pharmacists can be delivered sustainably, which ultimately protects and maintains equitable access to vaccination services for all Australians.”

 

Media contact: Georgia Clarke M: 0480 099 798 E: georgia.clarke@psa.org.au

 

Access to RSV vaccine critical to its efficacy

19 January 2024

 

Following the welcome approval of a new vaccine to protect older Australians against the highly infectious respiratory syncytial virus (RSV), the Pharmaceutical Society of Australia (PSA) is urging governments to ensure its accessibility for those most at risk.

This week the Therapeutic Goods Administration (TGA) approved AREXVY for Australians aged 60 and over, the first RSV vaccine approved in Australia.

PSA National President A/Prof Fei Sim FPS said that allowing pharmacists to administer the vaccine would significantly improve its uptake and in turn, reduce hospitalisations from severe infections.

“Having a vaccine on the market is not enough, we need to ensure that it’s as accessible as possible to those who need it most,” A/Prof Sim said.

“Pharmacist immunisers are limited by red-tape and regulation imposed by states and territories, preventing them from fulfilling their potential to administer all vaccines to all at-risk Australians.

“Millions of Australians attend pharmacies for their vaccinations, with more than 15 million COVID-19 and influenza vaccines administered by pharmacists over the last few years.

“By making vaccinations more accessible to vulnerable groups, we can limit the serious health complications RSV can cause and in turn reduce hospitalisations.

“Allowing pharmacists to practise to the top of their scope makes efficient use of health resources, benefitting the broader health system.

“I urge all state and territory governments to authorise pharmacists to provide the RSV vaccine, supporting access to preventive care and keeping older Australians healthy and well.

“This access should extend to all vaccines, for all eligible people, in all locations where pharmacists work.

“Reducing barriers to vaccination, reducing barriers to care, should always be our priority,” A/Prof Sim concluded.

AREXVY will soon be made available nationally, on private prescription.

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au